Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sex-differential responses to immune checkpoint inhibitors across the disease continuum unified by tumor mutational burden.

Seminars in oncology - 1 Dec 2025

Zheng Ming

Abstract excerpt

While the efficacy of immune checkpoint inhibitors (ICIs) in advanced non-small-cell lung cancer (NSCLC) is well-established, sex-based differences in treatment responses remain insufficiently explored. This study examines how sex disparities impact ICI treatment outcomes in advanced-stage NSCLC, focusing on the role of tumor mutational burden (TMB) in these differences. This study analyzed data from 174...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Non-Small-Cell Lung
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Sex Factors

Source

Identifiers

PMID: 40907130
DOI: 10.1016/j.seminoncol.2025.152414

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sex-differential responses to immune checkpoint inhibitors across the disease continuum unified by tumor mutational burden.PMID 40907130Read ↗

Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune EvasionSemantic proximity Read ↗

Sex-specific differences in immunogenomic features of response to immune checkpoint blockadeSemantic proximity Read ↗

Using a recently approved tumor mutational burden biomarker to stratify patients for immunotherapy may introduce a sex biasSemantic proximity Read ↗

Sex-specific predictive values of biomarkers for immunotherapy efficacy in lung adenocarcinomaSemantic proximity Read ↗

Somatic mutational landscape reveals mutational signatures and significantly mutated genes of cancer immunotherapeutic outcome and sex disparities.Semantic proximity Read ↗

Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific.Semantic proximity Read ↗

Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias.Semantic proximity Read ↗

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma.Semantic proximity Read ↗

Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients.Semantic proximity Read ↗

Integrated profile of tumor stage and mutational burden predicts disparate clinical responses to immune checkpoint inhibitors: A risk-benefit study.Semantic proximity Read ↗

Sex-based differences in lung cancer susceptibility and molecular genetics in the 2020sSemantic proximity Read ↗

Sex-biased adaptive immune regulation in cancer development and therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.